Trials / Completed
CompletedNCT00083928
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Ångstrom Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of CA 125 levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Å6 subcutaneous injection |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2006-02-01
- Completion
- 2006-12-01
- First posted
- 2004-06-07
- Last updated
- 2013-01-24
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00083928. Inclusion in this directory is not an endorsement.